Supporting Information

Synthesis and antitumor effect in vitro and in vivo of substituted 1,3-dihydroindole-2-ones.

Mette K. Christensen, Kamille D. Erichsen, Christina Trojel-Hansen, Jette Tjørnelund, Søren J. Nielsen, Karla Frydenvang, Tommy N. Johansen, Birgitte Nielsen, Maxwell Sehested, Peter Buhl Jensen, Martins Ikaunieks, Andrei Zaichenko, Einars Loza, Ivars Kalvinsh, and Fredrik Björkling.

Table of contents

	page
Experimentals	S2
General procedures	S2
Preparations and spectroscopic data of compounds 3-39	S2
X-Ray Crystallographic Analysis of compound 39	S13
Data Collection and Reduction compound 39	S13
Structure Solution and Refinement compound 39	S13
References	S15

Experimentals

Reaction conditions and yields were not optimized. ¹H and ¹³C NMR spectra were recorded on a Bruker Avance 300 spectrometer (300 MHz). Chemical shifts are reported in parts per million (δ) and referenced according to deuterated solvent for ¹H spectra (CDCl₃, 7.26; CD₃OD, 3.31; (CD₃)₂SO, 2.50) and ¹³C spectra (CDCl₃, 77.23; CD₃OD, 49.00; (CD₃)₂SO, 39.52). The value of a multiplet, either defined doublet (d), triplet (t), double doublet (dd), double triplet (dt), quartet (q)) or not (m) at the approximate mid point is given unless a range is quoted. (bs) indicates a broad singlet. The purity of the compounds was determined using an LC-MS (Bruker Esquire 3000+ ESI Iontrap with an Agilent 1200 HPLC-system) and was confirmed to be ≥95% for all compounds. HRMS was carried out on a Micromass *Q-Tof micro* mass spectrometer. The HPLC system for the semipreparative resolution of 39 consisted of a Jasco 880 pump, a Rheodyne 7125 injector, equipped with a 5 mL loop, and a Shimadzu SPD-6A UV detector, connected to a Hitachi-D2000 Chromato-integrator. A HPLC system for determination of the elution order of (*S*)-38 and (*R*)-38 consisting of a Dionex Ultimate 3000 pump, a TSP AS-3000 autosampler, and a Dionex Ultimate 3000 photodiode array detector was controlled by Chromeleon software v. 6.80.

General Procedure A: Grignard reaction to form tertiary alcohols of general formula II, followed by Friedel-Crafts reaction with phenol.

To a stirred solution of isatin derivative I in dry THF under nitrogen at –78 °C was added 3 eq. of Grignard reagent. After 30 min, the dry-ice bath was removed and the reaction was left to reach rt over 4 to 14 h.⁷ Excess Grignard reagent was quenched with water, and the reaction mixture was acidified with 1N HCl or saturated NH₄Cl-solution, extracted with EtOAc (×2), dried over MgSO₄, filtered and concentrated. The residue was purified by chromatography (1% MeOH in DCM or mixtures of petroleum ether and EtOAc) to afford racemic tertiary alcohol II.

To a solution of tertiary alcohol of general formula II in dichloroethane was added phenol (5 eq.) and p-TSA (7.5 eq.). The reaction mixture was heated to 90 °C for 2–4 h and then cooled to rt. The solid (mainly p-TSA) was filtered off and washed with dichloroethane or DCM. The solution was concentrated and the residue was purified by chromatography (1% MeOH in DCM or mixtures of petroleum ether and EtOAc) to afford racemic compounds of general formula III.

General Procedure B: HPLC purification on Daicel Chiralcel-OD column to yield pure enantiomers of general formula III.

Racemic compound of general formula III was dissolved in EtOH or EtOH/heptane mixtures and purified by HPLC on a Daicel Chiralcel-OD column (250×20 mm ID, 10 micron) to yield pure enantiomers of general formula III.

(*RS*)-6,7-Difluoro-3-(4-hydroxyphenyl)-3-phenylindolin-2-one (3). Preparation of 3 was performed according to general procedure A using 6,7-difluoroindoline-2,3-dione and phenylmagnesium bromide.

- (*RS*)-6,7–Difluoro-3-hydroxy-3-phenylindolin-2-one: 1 H NMR ((CD₃)₂SO) δ 11.19 (bs, 1H), 7.39–7.24 (m, 5H), 7.05–6.91 (m, 2H), 6.81 (s, 1H). Yield 55%.
- Product **3**: 1 H NMR ((CD₃)₂SO) δ 11.47 (bs, 1H), 9. 49 (bs, 1H), 7.37–7.25 (m, 3H), 7.18–7.12 (m, 2H), 7.09–7.00 (m, 2H), 6.96 (m, 2H), 6.72 (m, 2H). HRMS m/z calcd for $C_{20}H_{13}F_{2}NO_{2}$ [M+Na], 360.0812; found, 360.0899. Yield 83%.
- (*RS*)-6,7–Difluoro-3-(4-fluorophenyl)-3-(4-hydroxyphenyl)indolin-2-one (4). Preparation of 4 was performed according to general procedure A using 6,7-difluoroindoline-2,3-dione and 4-fluorphenylmagnesium bromide.
- (*RS*)-6,7–Difluoro-3-(4-fluorophenyl)-3-hydroxyindolin-2-one: 1 H NMR ((CD₃)₂SO) δ 11.22 (bs, 1H), 7.31 (dd, J = 5.0, 8.9 Hz, 2H), 7.16 (t, J = 9.0 Hz, 2H), 7.04–6.91 (m, 2H), 6.88 (s, 1H). Yield 93%.
- Product 4: 1 H NMR ((CD₃)₂SO) δ 11.49 (bs, 1H), 9. 50 (bs, 1H), 7.22–7.11 (m, 4H), 7.10–6.99 (m, 2H), 6.95 (m, 2H), 6.72 (m, 2H). HRMS m/z calcd for $C_{20}H_{12}F_{3}NO_{2}$ [M+Na], 378.0718; found, 374.0774. Yield 89%.
- (*RS*)-6,7–Difluoro-3-(4-hydroxyphenyl)-3-*p*-tolylindolin-2-one (5). Preparation of 5 was performed according to general procedure A using 6,7-difluoroindoline-2,3-dione and *p*-tolylmagnesium bromide.
- (*RS*)-6,7–Difluoro-3-hydroxy-3-*p*-tolylindolin-2-one: 1 H NMR ((CD₃)₂SO) δ 11.19 (bs, 1H), 7.13 (m, 4H), 7.05–6.88 (m, 2H), 6.73 (s, 1H). Yield 86%.
- Product **5**: 1 H NMR (CDCl₃) δ 8.28 (bs, 1H), 7.11 (m, 4H), 7.06 (m, 2H), 6.93–6.78 (m, 2H), 6.72 (m, 2H), 5.47 (bs, 1H), 2.31 (s, 3H). HRMS m/z calcd for $C_{21}H_{15}F_{2}NO_{2}$ [M+Na], 374.0969; found, 374.0955. Yield 85%.
- (*RS*)-6,7–Difluoro-3-(4-hydroxyphenyl)-3-(4-methoxyphenyl)indolin-2-one (6). Preparation of 6 was performed according to general procedure A using 6,7-difluoroindoline-2,3-dione and 4-methoxyphenylmagnesium bromide.
- (*RS*)-6,7–Difluoro-3-hydroxy 3-(4-methoxyphenyl)indolin-2-one: 1 H NMR ((CD₃)₂SO) δ 11.12 (bs, 1H), 7.20 (m, 2H), 7.04–6.91 (m, 2H), 6.89 (m, 2H), 6.71 (s, 1H), 3.33 (s, 3H). Yield 86%.
- Product **6**: ¹H NMR ((CD₃)₂SO) δ 11.42 (bs, 1H), 9. 47 (bs, 1H), 7.04 (m, 4H), 6.94 (d, J = 8.7 Hz, 2H), 6.89 (d, J = 8.9 Hz, 2H), 6.72 (d, J = 8.9 Hz, 2H), 3.72 (s, 3H). HRMS m/z calcd for C₂₁H₁₅F₂NO₃ [M+Na], 390.0918; found, 390.0902. Yield 92%.

- **6,7-Difluoro-3-(4-hydroxyphenyl)-3-(4-methoxyphenyl)indolin-2-one** (enantiomer 1) (6). Preparation of enantiomer 1 of compound **6** was performed according to general procedure B (heptane:EtOH 70:30, 15 mL/min) using racemic compound **6** as starting material. t_R (Chiralcel OD-H 250 × 4.6 mm ID, 5 micron, heptane:EtOH 70:30, 0.6 mL/min): 10.5 min. HRMS m/z calcd for $C_{21}H_{15}F_{2}NO_{3}$ [M+Na], 390.0918; found, 390.0902. Yield 37%.
- **6,7-Difluoro-3-(4-hydroxyphenyl)-3-(4-methoxyphenyl)indolin-2-one** (enantiomer 2) (6). Preparation of enantiomer 2 of compound **6** was performed according to general procedure B (heptane:EtOH 70:30, 15 mL/min) using racemic compound **6** as starting material. t_R (Chiralcel OD-H 250 × 4.6 mm ID, 5 micron, heptane:EtOH 70:30, 0.6 mL/min): 15.6 min. HRMS m/z calcd for $C_{21}H_{15}F_{2}NO_{3}$ [M+Na], 390.0918; found, 390.0883. Yield 40%.
- (*RS*)-3-(4-Ethoxyphenyl)-6,7-difluoro-3-(4-hydroxyphenyl)indolin-2-one (7). Preparation of 7 was performed according to general procedure A using 6,7-difluoroindoline-2,3-dione and 4-ethoxyphenylmagnesium bromide.
- (*RS*)-3-(4-Ethoxyphenyl)-6,7–difluoro-3-hydroxyindolin-2-one: 1 H NMR ((CD₃)₂SO) δ 11.13 (bs, 1H), 7.18 (m, 2H), 7.00 (m, 2H), 6.87 (m, 2H), 6.71 (s, 1H), 3.99 (q, J = 7.0 Hz, 2H), 1.30 (t, J = 7.0 Hz, 3H). Yield 62%.
- Product 7: 1 H NMR (CDCl₃) δ 8.66 (bs, 1H), 7.15 (m, 2H), 7.06 (m, 2H), 6.95–6.85 (m, 2H), 6.83(m, 2H), 6.72 (m, 2H), 6.20 (bs, 1H), 4.01 (q, J = 7.1 Hz, 2H), 1.40 (t, J = 7.1 Hz, 3H). HRMS m/z calcd for C₂₂H₁₇F₂NO₃ [M+Na], 404.1074; found, 404.049. Yield 85%.
- (*RS*)-6,7-Difluoro-3-(4-hydroxyphenyl)-3-(4-propoxyphenyl)indolin-2-one (8). Preparation of 8 was performed according to general procedure A using 6,7-difluoroindoline-2,3-dione and 4-propoxyphenylmagnesium bromide.
- (*RS*)-6,7-Difluoro-3-hydroxy-3-(4-propoxyphenyl)indolin-2-one: 1 H NMR ((CD₃)₂SO) δ 10.41 (bs, 1H), 7.79 (m, 2H), 7.49 (m, 1H), 7.40 (m, 1H), 7.34 (m, 2H), 6.09 (s, 1H), 4.38 (t, J = 6.5 Hz, 2H), 2.20 (m, 2H), 1.45 (t, J = 7.4, 3H). Yield 40%.
- Product **8**: ¹H NMR (CDCl₃) δ 8.67 (bs, 1H), 7.13 (m, 2H), 7.05 (m, 2H), 6.87 (m, 2H), 6.81 (m, 2H), 6.70 (m, 2H), 6.28 (bs, 1H), 3.87 (q, J = 6.5 Hz, 2H), 1.78 (m, 2H), 1.01 (t, J = 7.5 Hz, 3H). HRMS m/z calcd for $C_{23}H_{19}F_{2}NO_{3}$ [M+Na], 418.1231; found, 404.1245. Yield 94%.
- (*RS*)-6,7–Difluoro-3-(4-hydroxyphenyl)-3-[4-(pentyloxy)phenyl]indolin-2-one (9). Preparation of 9 was performed according to general procedure A using 6,7-difluoroindoline-2,3-dione and 4-(pentyloxy)phenylmagnesium bromide.
- (*RS*)-6,7–Difluoro-3-hydroxy-3-[4-(pentyloxy)phenyl]-indolin-2-one: 1 H NMR ((CD₃)₂SO) δ 10. (bs, 1H), 7.79 (m, 2H), 7.49 (m, 1H), 7.40 (m, 1H), 7.34 (m, 2H), 6.09 (s, 1H), 4.42 (t, J = 6.5 Hz, 2H), 2.50 (m, 2H), 1.85 (m, 4H), 1.36 (t, J = 7.1 Hz, 3H). Yield 80%.
- Product 9: 1 H NMR (CDCl₃) δ 8.77 (bs, 1H), 7.13 (m, 2H), 7.04 (m, 2H), 6.87 (m, 2H), 6.81 (m, 2H), 6.69 (m, 2H), 6.30 (bs, 1H), 3.91 (q, J = 6.4 Hz, 2H), 1.76 (m, 2H), 1.39 (m, 4H), 0.92 (t, J = 6.7 Hz, 3H). HRMS m/z calcd for $C_{25}H_{23}F_{2}NO_{3}$ [M+Na], 446.1544; found, 446.1621. Yield 59%.

- (*RS*)-6,7–Difluoro-3-(3-hydroxyphenyl)-3-(4-methoxyphenyl)indolin-2-one (10). Preparation of 10 was performed according to general procedure A (step 1) using 6,7-difluoroindoline-2,3-dione and 3-methoxyphenylmagnesium bromide.
- (*RS*)-6,7-Difluoro-3-hydroxy-3-(3-methoxyphenyl)indolin-2-one: 1 H NMR ((CD₃)₂SO) δ 11.19 (bs, 1H), 7.21 (t, J = 7.9 Hz, 1H), 6.94 (m, 3H), 6.86 (m, 1H), 6.82 (bs, 1H), 6.70 (m, 1H), 3.73 (s, 3H). Yield 85%.
- 6,7-Difluoro-3-hydroxy-3-(3-methoxyphenyl)indolin-2-one (1.0 mmol) was suspended in DCM, cooled to -78 °C under N₂, followed by dropwise additon of BBr₃ (2.0 mmol). The reaction mixture was gradually allowed to reach rt and stirred overnight, quenched with water, extracted three times with diethyl ether. The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated. The residue was purified by chromatography (1% MeOH in DCM) to afford 6,7-difluoro-3-hydroxy-3-(3-hydroxyphenyl)indolin-2-one. ¹H NMR ((CD₃)₂SO) δ 11.15 (bs, 1H), 9.38 (bs, 1H), 7.09 (t, J = 7.9 Hz, 1H), 6.96 (m, 2H), 6.75 (m, 1H), 6.72 (bs, 1H), 6.65 (m, 1H). Yield 93%.

To a suspension of 6,7-difluoro-3-hydroxy-3-(3-hydroxyphenyl)indolin-2-one in dichloroethane was added anisol (5 eq.) and p-TSA (7.5 eq.). The reaction mixture was heated to 90 °C for 4 h and then cooled to rt. The solid (mainly p-TSA) was filtered off and washed with DCM. The filtrate was concentrated and the residue was purified by chromatography (1% MeOH in DCM) to afford compound **10.** 1 H NMR ((CD₃)₂SO) δ 11.47 (bs, 1H), 9. 38 (bs, 1H), 7.16–7.00 (m, 5H), 6.90 (m, 2H), 6.67 (m, 1H), 6.58 (m, 1H), 6.54 (m, 1H), 3.73 (s, 3H). HRMS m/z calcd for C₂₁H₁₅F₂NO₃ [M+H], 368.1098; found, 368.1094. Yield 69%.

- (*RS*)-3-(3,4-Difluorophenyl)-6,7-difluoro-3-(4-hydroxyphenyl)indolin-2-one (11). Preparation of 11 was performed according to general procedure A using 6,7-difluoroindoline-2,3-dione and 3,4-difluorophenylmagnesium bromide.
- (*RS*)-3-(3,4-Difluorophenyl)-6,7-difluoro-3-hydroxyindolin-2-one: 1 H NMR ((CD₃)₂SO) δ 11.73 (bs, 1H), 8.11 (m, 1H), 8.03 (bs, 1H), 7.72 (m, 1H), 7.49 (m, 2H), 6.99 (bs, 1H). Yield 60%.
- Product **11**: 1 H NMR (CDCl₃) δ 8.04 (bs, 1H), 7.20–7.00 (m, 4H), 7.00–6.84 (m, 3H), 6.77 (m, 2H), 5.12 (bs, 1H). HRMS m/z calcd for $C_{20}H_{11}F_{4}NO_{2}$ [M+H], 374.0804; found, 374.0797. Yield 98%.
- (*RS*)-6,7-Difluoro-3-(4-hydroxyphenyl)-3-(thiophen-2-yl)indolin-2-one (12). Preparation of 12 was performed according to general procedure A using 6,7-difluoroindoline-2,3-dione and thiophen-2-ylmagnesium bromide.
- (*RS*)-6,7-Difluoro-3-hydroxy-3-(thiophen-2-yl)indolin-2-one: 1 H NMR ((CD₃)₂SO) δ 11.23 (bs, 1H), 7.52 (dd, J = 1.3, 5.1 Hz, 1H), 7.16 (m, 1H), 7.06 (m, 1H) 7.05 (s, 1H), 6.95 (dd, J = 3.56, 5.1 Hz 1H), 6.71 (dd, J = 1.3, 3.6 Hz, 1H). Yield 41%.
- Product **12**: ¹H NMR ((CD₃)₂SO) δ 11.55 (bs, 1H), 9.53 (bs, 1H), 7.51 (d, J = 5.5 Hz, 1H), 7.16 (m, 1H), 7.08 (m, 1H), 7.0–6.9 (m, 4H), 6.70 (m, 2H). HRMS m/z calcd for C₁₈H₁₁F₂NO₂S [M+H], 344.0558; found, 344.0557. Yield 66%.

- (*RS*)-6,7-Difluoro-3-(4-hydroxyphenyl)-3-(pyridin-4-yl)indolin-2-one (13). Preparation of 13 was performed according to general procedure A using 6,7-difluoroindoline-2,3-dione and pyridin-4-ylmagnesium bromide.
- (RS)-6,7-Difluoro-3-hydroxy-3-(pyridin-4-yl)indolin-2-one: 1 H NMR ((CD₃)₂SO) δ 11.37 (bs, 1H), 8.53 (m, 2H), 7.27 (m, 2H), 7.08 (s, 1H), 7.06-6.9 (m, 2H). Yield 43%.
- Product **13**: 1 H NMR ((CD₃)₂SO) δ 10.87 (bs, 1H), 8.99 (bs, 3H), 7.69 (bs, 2H), 7.68–7.40 (m, 4H), 7.27 (m, 2H). HRMS m/z calcd for C₁₉H₁₂F₂N₂O₂ [M+H], 339.0945; found, 339.0928. Yield 18%.
- (*RS*)-6,7-Difluoro-3-(4-hydroxyphenyl)-3-(pyridin-3-yl)indolin-2-one (14). Preparation of 14 was performed according to general procedure A using 6,7-difluoroindoline-2,3-dione and pyridin-3-ylmagnesium bromide.
- (*RS*)-6,7-Difluoro-3-hydroxy-3-(pyridin-3-yl)indolin-2-one: 1 H NMR (CDCl₃) δ 8.61 (bs, 1H), 8.37 (m, 1H), 8.15 (1H, bs), 7.69 (m, 1H), 7.16 (m, 1H), 6.89 (m, 1H), 6.73 (m, 1H), 5.23 (s, 1H). Yield 10%. Product **14:** MS [M+K]⁺= 380.20. HRMS *m/z* calcd for $C_{19}H_{12}F_{2}N_{2}O_{2}$ [M+H], 339.0945; found, 339.0943. Yield 10%.
- (*RS*)-6,7-Difluoro-3-(4-hydroxyphenyl)-3-propylindolin-2-one (15). Preparation of 15 was performed according to general procedure A using 6,7-difluoroindoline-2,3-dione and *n*-propylmagnesium bromide.
- (*RS*)-6,7-Difluoro-3-hydroxy-3-propylindolin-2-one: 1 H NMR ((CD₃)₂SO) δ 11.00 (bs, 1H), 7.09 (m, 1H), 6.98 (m, 1H), 6.01 (s, 1H), 1.74 (m, 2H), 1.1-0.9 (m, 2H), 0.78 (t, J = 7.3 Hz, 3H). Yield 37%.
- Product **15**: 1 H NMR ((CD₃)₂SO) δ 11.20 (bs, 1H), 9.38 (bs, 1H), 7.04 (m, 4H), 6.69 (m, 2H), 2.13 (m, 2H), 1.21 (m, 2H), 1.02 (m, 2H), 0.83 (m, 3H). HRMS m/z calcd for C₁₇H₁₅F₂NO₂ [M+Na], 326.0969; found, 326.0996. Yield 96%.
- (*RS*)-6,7-Difluoro-3-(4-hydroxyphenyl)-3-pentylindolin-2-one (16). Preparation of 16 was performed according to general procedure A using 6,7-difluoroindoline-2,3-dione and *n*-pentylmagnesium bromide.
- (*RS*)-6,7-Difluoro-3-hydroxy-3-pentylindolin-2-one: 1 H NMR ((CD₃)₂SO) δ 11.00 (bs, 1H), 7.09 (m, 1H), 6.98 (m, 1H), 6.01 (s, 1H), 1.76 (m, 2H), 1.35-0.8 (m, 6H), 0.78 (t, J = 6.7 Hz, 3H). Yield 46%.
- Product **16**: 1 H NMR ((CD₃)₂SO) δ 11.21 (bs, 1H), 9.39 (bs, 1H), 7.04 (m, 4H), 6.70 (m, 2H), 2.20 (m, 2H), 1.18 (m, 4H), 1.00 (m, 1H), 0.9–0.65 (m, 4H). HRMS m/z calcd for $C_{19}H_{19}F_{2}NO_{2}$ [M+Na], 354.1282; found, 354.1290. Yield 80%.
- (*RS*)-3-Cyclopentyl-6,7-difluoro-3-(4-hydroxyphenyl)indolin-2-one (17). Preparation of 17 was performed according to general procedure A using 6,7-difluoroindoline-2,3-dione and cyclopentylmagnesium bromide.
- (RS)-3-Cyclopentyl-6,7-difluoro-3-hydroxyindolin-2-one: 1 H NMR ((CD₃)₂SO) δ 10.98 (bs, 1H), 7.15 (m, 1H), 6.94 (m, 1H), 2.31 (m, 1H), 1.7–1.3 (m, 7H), 1.15 (m, 1H). Yield 42%.

- Product **17**: 1 H NMR ((CD₃)₂SO) δ 11.21 (bs, 1H), 9.38 (bs, 1H), 7.12 (m, 3H), 7.01 (m, 1H), 6.69 (m, 2H), 2.97 (m, 1H), 1.6–1.2 (m, 7H), 0.94 (m, 1H). HRMS m/z calcd for $C_{19}H_{17}F_{2}NO_{2}$ [M+H], 330.1306; found, 330.1312. Yield 57%.
- (*RS*)-3-Cyclohexyl-6,7-difluoro-3-(4-hydroxyphenyl)indolin-2-one (18). Preparation of 18 was performed according to general procedure A using 6,7-difluoroindoline-2,3-dione and cyclohexylmagnesium chloride.
- (*RS*)-3-Cyclohexyl-6,7-difluoro-3-hydroxyindolin-2-one: 1 H NMR ((CD₃)₂SO) δ 10.98 (bs, 1H), 7.05 (m, 1H), 6.95 (m, 1H), 1.9-1.4 (m, 6H), 1.25-0.85 (m, 4H), 0.67 (m, 1H). Yield 55%.
- Product **18**: 1 H NMR ((CD₃)₂SO) δ 11.19 (bs, 1H), 9.39 (bs, 1H), 7.12 (m, 3H), 7.03 (m, 1H), 6.70 (m, 2H), 2.33 (m, 1H), 1.7–0.8 (m, 9H), 0.71 (m, 1H). HRMS m/z calcd for $C_{20}H_{19}F_{2}NO_{2}$ [M+H], 344.1462; found, 344.1453. Yield 93%.
- **3-Cyclohexyl-6,7-difluoro-3-(4-hydroxyphenyl)indolin-2-one (enantiomer 1) (18).** Preparation of enantiomer 1 of compound **18** was performed according to general procedure B (heptane:ethanol 70:30, 7 mL/min). Starting material: racemic compound **18**. t_R (Chiralcel OD-H 250 × 4.6 mm ID, 5 micron, heptane:ethanol 70:30, 0.6 mL/min): 8.9 min. HRMS m/z calcd for $C_{20}H_{19}F_2NO_2$ [M+H], 344.1462; found, 344.1448, Yield 39%.
- **3-Cyclohexyl-6,7-difluoro-3-(4-hydroxyphenyl)indolin-2-one (enantiomer 2) (18).** Preparation of enantiomer 2 of compound **18** was performed according to general procedure B (heptane:ethanol 70:30, 7 mL/min). Starting material: racemic compound **18**. t_R (Chiralcel OD-H 250 × 4.6 mm ID, 5 micron, heptane:ethanol 70:30, 0.6 mL/min): 14.5 min. HRMS m/z calcd for $C_{20}H_{19}F_2NO_2$ [M+Na], 366.1282; found, 366.1275. Yield 34%.
- (*RS*)-3-Cycloheptyl-6,7-difluoro-3-(4-hydroxyphenyl)indolin-2-one (19). Preparation of 19 was performed according to general procedure A using 6,7-difluoroindoline-2,3-dione and cycloheptylmagnesium bromide.
- (*RS*)-3-Cycloheptyl-6,7-difluoro-3-hydroxyindolin-2-one: 1 H NMR ((CD₃)₂SO) δ 10.99 (bs, 1H), 7.06 (m, 1H), 6.94 (m, 1H), 2.06 (m, 1H), 1.91 (m, 1H) 1.8–1.1 (m, 10H), 0.78 (m, 1H). Yield 42%.
- Product **19**: 1 H NMR ((CD₃)₂SO) δ 11.16 (bs, 1H), 9.39 (bs, 1H), 7.08 (m, 4H), 6.70 (m, 2H), 2.53 (m, 1H), 1.7–1.15 (m, 11H), 0.84 (m, 1H). HRMS m/z calcd for $C_{21}H_{21}F_{2}NO_{2}$ [M+H], 358.1619; found, 358.1622. Yield 90%.
- (*RS*)-3-Cyclooctyl-6,7-difluoro-3-(4-hydroxyphenyl)indolin-2-one (20). Preparation of 20 was performed according to general procedure A using 6,7-difluoroindoline-2,3-dione and cyclooctylmagnesium bromide.
- (*RS*)-3-Cyclooctyl-6,7-difluoro-3-hydroxyindolin-2-one: 1 H NMR ((CD₃)₂SO) δ 11.01 (bs, 1H), 7.08 (m, 1H), 6.94 (m, 1H), 6.00 (s, 1H), 2.03 (m, 1H), 1.8–1.2 (m, 13 H), 0.85 (m, 1H). Yield 28%.

- Product **20**: 1 H NMR ((CD₃)₂SO) δ 11.16 (bs, 1H), 9.40 (bs, 1H), 7.11 (m, 3H), 7.02 (m, 1H), 6.70 (m, 2H), 2.64 (m, 1H), 1.65–1.15 (m, 13H), 0.89 (m, 1H). HRMS m/z calcd for $C_{22}H_{23}F_{2}NO_{2}$ [M+H], 372.1775; found, 372.1755. Yield 43%.
- (*RS*)-3-(Cyclohexylmethyl)-6,7-difluoro-3-(4-hydroxyphenyl)indolin-2-one (21). Preparation of 21 was performed according to general procedure A using 6,7-difluoroindoline-2,3-dione and cyclohexylmethylmagnesium bromide.
- (*RS*)-3-(Cyclohexylmethyl)-6,7-difluoro-3-hydroxy-indolin-2-one: 1 H-NMR ((CD₃)₂SO) δ 11.00 (bs, 1H), 7.10 (m, 1H), 6.98 (m, 1H), 5.95 (s, 1H), 1.75 (d, 2H), 1.6–1.4 (m, 4H), 1.32 (m, 1H), 1.02 (m, 4H), 0.82 (m, 2H). Yield 42%.
- Product **21**:¹H NMR ((CD₃)₂SO) δ 11.19 (bs, 1H), 9.37 (bs, 1H), 7.07 (m, 2H), 7.05 (m, 2H), 6.67 (d, 2H), 2.12 (m, 2H), 1.6–1.4 (m, 4H), 1.25 (m, 1H), 1.1–0.7 (m, 6H). HRMS m/z calcd for C₂₁H₂₁F₂NO₂ [M+Na], 380.1438; found, 380.1403. Yield 67%.
- (*RS*)-3-Benzyl-6,7-difluoro-3-(4-hydroxyphenyl)indoline-2-one (22). Preparation of 22 was performed according to general procedure A using 6,7-difluoroindoline-2,3-dione and benzylmagnesium chloride.
- (*RS*)-3-Benzyl-6,7-difluoro-3-hydroxyindolin-2-one: 1 H NMR ((CD₃)₂SO) δ 10.86 (bs, 1H), 7.3-6.7 (m, 7H), 6.33 (1H, bs), 3.10 (dd, 2H). Yield 85%.
- Product **22**: 1 H NMR ((CD₃)₂SO) δ 10.99 (bs, 1H), 9.44 (s, 1H), 7.18 (m, 3H), 7.08 (m, 3H), 6.99 (m, 1H), 6.89 (m, 2H), 6.74 (m, 2H), 3.50 (dd, 2H). HRMS m/z calcd for C₂₁H₁₅F₂NO₂ [M+Na], 374.0969; found, 374.0957. Yield 82%.
- (*RS*)-3-(4-Fluorophenyl)-3-(4-hydroxyphenyl)indolin-2-one (23). Preparation of 23 was performed according to general procedure A using indoline-2,3-dione and 4-fluorophenylmagnesium bromide.
- (*RS*)-3-(4-Fluorophenyl)-3-hydroxy-indolin-2-one: 1 H-NMR ((CD₃)₂SO) δ 10.42 (bs, 1H), 7.29 (m, 3H), 7.14 (m, 3H), 6.98 (t, J = 7.5 Hz, 1H), 6.90 (d, J = 7.5 Hz, 1H), 6.69 (s, 1H). Yield 67%.
- Product **23**: 1 H NMR ((CD₃)₂SO) δ 10.71 (bs, 1H), 9.45 (bs, 1H), 7.22 (m, 2H), 7.15 (m, 4H), 7.01 (m, 1H), 6.94 (m, 3H), 6.70 (m, 2H). HRMS m/z calcd for C₂₀H₁₄FNO₂ [M+Na], 342.0906; found, 342.0886. Yield 95%.
- (*RS*)-3-Cycloheptyl-3-(4-hydroxyphenyl)indolin-2-one (24). Preparation of 24 was performed according to general procedure A using indoline-2,3-dione and cycloheptylmagnesium bromide.
- (*RS*)-3-Cycloheptyl-3-hydroxy-indolin-2-one: 1 H-NMR ((CD₃)₂SO) δ 10.19 (bs, 1H), 7.22 (d, J = 7.0 Hz, 3H), 7.17 (m, 1H), 6.92 (m, 1H), 6.77 (d, J = 7.5 Hz, 1H), 5.77 (s, 1H). Yield 26%.
- Product **24**: 1 H NMR ((CD₃)₂SO) δ 10.36 (bs, 1H), 9.32 (bs, 1H), 7.28 (d, J = 7.5 Hz ,1H), 7.23 (m, 1H), 7.10 (m, 2H), 7.02 (m, 1H), 6.87 (d, J = 7.2 Hz, 1H), 6.68 (m, 2H), 2.46 (m, 1H), 1.7–1.15 (m, 11H), 0.84 (m, 1H). HRMS m/z calcd for C₂₁H₂₃NO₂ [M+Na], 344.1626; found, 344.1645. Yield 63%.

(*RS*)-3-Cycloheptyl-3-(4-hydroxyphenyl)-7-methylindolin-2-one (25). Preparation of 25 was performed according to general procedure A using 7-methylindoline-2,3-dione and cycloheptylmagnesium bromide.

(*RS*)-3-Cycloheptyl-3-hydroxy-7-methylindolin-2-one: 1 H-NMR ((CD₃)₂SO) δ 10.24 (bs, 1H), 7.05 (d, J = 7.4 Hz, 1H), 7.01 (d, J = 7.4 Hz, 1H), 6.85 (t, J = 7.4 Hz, 1H), 5.73 (s, 1H), 2.17 (s, 3H), 2.07 (m, 1H), 1.80 (m, 1H), 1.72 (m, 1H), 1.6–1.15 (m, 9H), 0.75 (m, 1H). Yield 14%.

Product **25**: 1 H NMR ((CD₃)₂SO) δ 10.39 (bs, 1H), 9.31 (bs, 1H), 7.09 (m, 3H), 7.05 (d, J = 7.4 Hz, 1H), 6.93 (t, J = 7.4 Hz, 1H), 6.67 (m, 2H), 2.46 (m, 1H), 2.21 (s, 3H), 1.7–1.2 (m, 9H), 0.84 (m, 1H). HRMS m/z calcd for C₂₂H₂₅NO₂ [M+H], 336.1964; found, 336.1940. Yield 68%.

(*RS*)-3-Cycloheptyl-3-(4-hydroxyphenyl)-7-(trifluoromethyl)indolin-2-one (26). Preparation of 26 was performed according to general procedure A using 7-(trifluoromethyl)indoline-2,3-dione and cycloheptylmagnesium bromide.

(*RS*)-3-Cycloheptyl-3-hydroxy-7-(trifluoromethyl)indolin-2-one: 1 H NMR (CDCl₃) δ 10.72 (bs, 1H), 7.50 (m, 2H), 7.12 (t, J = 7.7 Hz, 1H), 6.03 (s, 1H), 2.2–1.1 (m, 12H), 0.80 (m, 1H). Yield 26%.

Product **26**: ¹H NMR ((CD₃)₂SO) δ 10.90 (bs, 1H), 9.41 (bs, 1H), 7.56 (m, 2H), 7.20 (t, J = 7.5 Hz, 1H), 7.09 (m, 2H), 6.71 (m, 2H), 2.55 (m, 1H), 1.7–1.15 (m, 11H), 0.86 (m, 1H). HRMS m/z calcd for C₂₂H₂₂F₃NO₂ [M+Na], 390.1681; found, 390.1662. Yield 49%.

(RS)-3-(4-(hydroxyphenyl)-3-(1H-imidazol-1-yl)-7-(trifluoromethyl)indolin-2-one (27).

Preparation of **27** was performed according to general procedure A (step 1) using 7- (trifluoromethyl)indoline-2,3-dione and (4-(benzyloxy)phenyl)magnesium bromide followed by two additional steps (see below).

(*RS*)-3-(4-(Benzyloxy)phenyl)-3-hydroxy-7-(trifluoromethyl)indolin-2-one: 1 H-NMR (DMSO-d₆) δ 10.85 (bs, 1H), 7.55 (d, J = 8.7 Hz, 1H), 7.5–7.28 (m, 6H), 7.18 (m, 3H), 6.98 (m, 2H), 6.75 (s, 1H), 5.08 (s, 2H). Yield 69%.

Imidazole (204 mg, 3 mmol) was dissolved in DCM (dried), cooled to 0 $^{\circ}$ C, and thionylchloride (55 µL, 0.75 mmol) was added with stirring. After 30 min 3-(4-(benzyloxy)phenyl)-3-hydroxy-7-(trifluoromethyl)indolin-2-one (200 mg, 0.5 mmol) was added. After a further 2 h the reaction mixture was extracted with H₂O, brine, dried over MgSO₄, filtered and concentrated. The residue was purified by chromatography (1% MeOH in DCM) to afford 3-(4-(benzyloxy)phenyl)-3-(1*H*-imidazol-1-yl)-7-(trifluoromethyl)indolin-2-one. 1 H-NMR (DMSO-d₆) δ 11.59 (bs, 1H), 7.82 (d, J = 7.4 Hz, 1H), 7.69 (d, J = 8.3 Hz, 1H), 7.59 (s, 1H), 7.5–7.2 (m, 6H), 7.15–6.95 (m, 6H), 5.10 (s, 2H). Yield 81%.

 $3\text{-}(4\text{-}(benzyloxy)phenyl)-3\text{-}(1H\text{-}imidazol-1\text{-}yl)-7\text{-}(trifluoromethyl)indolin-2\text{-}one (184 mg, 0.36 mmol) was dissolved in MeOH (10 mL) and the solution bubbled through with <math display="inline">N_2$ for 2 minutes. 10% Pd/C (60 mg) was added. The flask was fitted with a septum and a $N_2\text{-}filled$ balloon, carefully evacuated and filled with N_2 . The $N_2\text{-}filled$ balloon was substituted with a $H_2\text{-}filled$ balloon, the flask was then carefully evacuated and filled with H_2 twice and the reaction mixture vigorously stirred at rt for 4h. The flask was the carefully evacuated and

- filled with N₂ twice, the reaction mixture filtered through Celite, concentrated and purified by flash chromatography (1%–5% MeOH in DCM) to yield product **27**. ¹H-NMR (DMSO-d₆) δ 11.53 (bs, 1H), 9.79 (bs, 1H), 7.78 (d, J = 7.2 Hz, 1H), 7.68 (d, J = 8.3 Hz, 1H), 7.56 (bs, 1H), 7.28 (t, J = 7.2 Hz, 1H), 7.10 (bs, 1H), 7.01 (m, 3H), 6.80 (m, 2H). HRMS m/z calcd for C₁₈H₁₂F₃N₃O₂ [M+Na], 382.0779; found, 382.0772. Yield 38%.
- (*RS*)-3-(4-Fluorophenyl)-3-(4-hydroxyphenyl)-5,7-dimethylindolin-2-one (28). Preparation of 28 was performed according to general procedure A using 5,7-dimethylindoline-2,3-dione and 4-fluorophenylmagnesium bromide.
- (*RS*)-3-(4-Fluorophenyl)-3-hydroxy-5,7-dimethylindolin-2-one: 1 H-NMR ((CD₃)₂SO) δ 10.36 (bs, 1H), 7.28 (m, 2H), 7.13 (m, 2H), 6.88 (bs, 1H), 6.73 (bs, 1H), 5.59 (s, 1H), 2.20 (s, 3H), 2.18 (s, 3H). Yield 63%.
- Product **28:** 1 H NMR ((CD₃)₂SO) δ 10.63 (bs, 1H), 9.42 (bs, 1H), 7.15 (m, 4H), 6.95 (m, 2H), 6.86 (bs, 1H), 6.82 (bs, 1H), 6.70 (m, 2H), 2.21 (s, 3H), 2.20 (s, 3H). HRMS m/z calcd for C₂₀H₁₈FNO₂ [M+H], 348.1400; found, 348.1406. Yield 95%.
- (*RS*)-3-Cycloheptyl-3-(4-hydroxyphenyl)-5,7-dimethylindolin-2-one (29). Preparation of 29 was performed according to general procedure A using 5,7-dimethylindoline-2,3-dione and cycloheptylmagnesium bromide.
- (*RS*)-3-Cycloheptyl-3-hydroxy-5,7-dimethylindolin-2-one: 1 H-NMR ((CD₃)₂SO) δ 10.13 (bs, 1H), 6.86 (bs, 1H), 6.81 (bs, 1H), 5.66 (s, 1H), 2.21 (s, 3H), 2.13 (s, 3H), 2.07 (m, 1H), 1.87 (m, 1H), 1.71 (m, 1H), 1.65–1.15 (m, 9H), 0.76 (m, 1H). Yield 34%.
- Product **29**: 1 H NMR ((CD₃)₂SO) δ 10.28 (bs, 1H), 9.31 (bs, 1H), 7.10 (m, 2H), 6.90 (bs, 1H), 6.85 (bs, 1H), 6.68 (m, 2H), 2.46 (m, 1H), 2.26 (s, 3H), 2.17 (s, 3H), 1.7–1.1 (m, 11H), 0.85 (m, 1H). HRMS m/z calcd for C₂₃H₂₇NO₂ [M+Na], 372.1939; found, 372.1938. Yield 60%.
- (*RS*)-3-Cycloheptyl-5-fluoro-3-(4-hydroxyphenyl)-7-methylindolin-2-one (30). Preparation of 30 was performed according to general procedure A using 5-fluoro-7-methylindoline-2,3-dione and cycloheptylmagnesium bromide.
- (*RS*)-3-Cycloheptyl-5-fluoro-3-hydroxy-7-methylindolin-2-one: 1 H-NMR ((CD₃)₂SO) δ 10.30 (bs, 1H), 6.88 (m, 2H), 5.88 (s, 1H), 2.18 (s, 3H), 2.02 (m, 1H), 1.90 (m, 1H), 1.70 (m, 1H), 1.65–1.15 (m, 9H), 0.79 (m, 1H). Yield 35%.
- Product **30**: 1 H NMR ((CD₃)₂SO) δ 10.45 (bs, 1H), 9.35 (bs, 1H), 7.10 (m, 2H), 6.95 (m, 2H), 6.69 (m, 2H), 2.46 (m, 1H), 2.21 (s, 3H), 1.7–1.2 (m, 11H), 0.86 (m, 1H). HRMS m/z calcd for C₂₂H₂₄FNO₂ [M+Na], 376.1689; found, 378.1696. Yield 57%.
- (*RS*)-3-Cycloheptyl-3-(4-hydroxyphenyl)-6,7-dimethylindolin-2-one (31). Preparation of 31 was performed according to general procedure A using 6,7-dimethylindoline-2,3-dione and cycloheptylmagnesium bromide.
- (*RS*)-3-Cycloheptyl-3-hydroxy-6,7-dimethylindolin-2-one: 1 H NMR ((CD₃)₂SO δ 10.16 (bs, 1H), 6.93 (d, J = 7.6 Hz, 1H), 6.74 (d, J = 7.6 Hz, 1H,), 5.62 (s, 1H), 2.18 (s, 3H), 2.08 (s, 3H), 2.05 (m, 1H), 1.88 (m, 1H), 1.71 (m, 1H), 1.6–1.15 (m, 9H), 0.75 (m, 1H). Yield 28%.
- Product **31**: ¹H NMR ((CD₃)₂SO) δ 10.30 (bs, 1H), 9.29 (bs, 1H), 7.10 (m, 2H), 6.98 (d, J = 7.7 Hz, 1H), 6.83 (d, J = 7.7 Hz, 1H), 6.66 (m, 2H), 2.45 (m, 1H), 2.22 (s, 3H), 2.12 (s, 3H),

- 1.7-1.15 (m, 11H), 0.84 (m, 1H). HRMS m/z calcd for $C_{23}H_{27}NO_2$ [M+H], 350.2120; found, 350.2097. Yield 72%.
- (*RS*)-**3-Cycloheptyl-6-fluoro-3-(4-hydroxyphenyl)-7-methylindolin-2-one (32).** Preparation of **32** was performed according to general procedure A using 6-fluoro-7-methylindoline-2,3-dione and cycloheptylmagnesium bromide.
- (*RS*)-3-Cycloheptyl-6-fluoro-3-hydroxy-7-methylindolin-2-one: 1 H NMR (CDCl₃) δ 8.56 (bs, 1H), 7.16 (m, 1H), 6.71 (m, 1H), 2.84 (m, 1H), 2.18 (s, 3H), 2.3–1.3 (m, 11H), 0.88 (m, 1H). Yield 27%.
- Product **32**: 1 H NMR ((CD₃)₂SO) δ 10.62 (bs, 1H), 9.35 (bs, 1H), 7.10 (m, 3H), 6.80 (m, 1H), 6.68 (m, 2H), 2.47 (m, 1H), 2.14 (s, 3H), 1.7–1.1 (m, 11H), 0.84 (m, 1H). HRMS m/z calcd for C₂₂H₂₄FNO₂ [M+Na], 376.1689; found, 376.1689. Yield 57%.
- (*RS*)-6-Chloro-3-cycloheptyl-3-(4-hydroxyphenyl)-7-methylindolin-2-one (33). Preparation of 33 was performed according to general procedure A using 6-chloro-7-methylindoline-2,3-dione and cycloheptylmagnesium bromide.
- (*RS*)-6-chloro-3-cycloheptyl-3-hydroxy-7-methylindolin-2-one: 1 H-NMR ((CD₃)₂SO) δ 10.48 (bs, 1H), 7.07 (d, J = 7.9 Hz, 1H), 7.01 (d, J = 7.9 Hz, 1H), 5.85 (s, 1H), 2.21 (s, 3H), 2.04 (m, 1H), 1.90 (m, 1H), 1.71 (m, 1H), 1.6.1-1.1 (m, 9H), 0.79 (m, 1H). Yield 36%.
- Product **33:** 1 H NMR ((CD₃)₂SO) δ 10.62 (bs, 1H), 9.35 (bs, 1H), 7.09 (m, 4H), 6.69 (m, 2H), 2.25 (s, 3H), 1.7–1.15 (m, 12H), 0.85 (m, 1H). HRMS m/z calcd for C₂₂H₂₄ClNO₂ [M+H], 370.1574; found, 370.1532. Yield 65%.
- (*RS*)-7-Chloro-3-cycloheptyl-3-(4-hydroxyphenyl)-6-methylindolin-2-one (34). Preparation of 34 was performed according to general procedure A using 7-chloro-6-methylindoline-2,3-dione and cycloheptylmagnesium bromide.
- (*RS*)-7-chloro-3-cycloheptyl-3-hydroxy-6-methylindolin-2-one: 1 H-NMR ((CD₃)₂SO) δ 10.55 (bs, 1H), 7.09 (d, J = 7.4 Hz, 1H), 6.92 (d, J = 7.4 Hz, 1H), 5.90 (s, 1H), 2.29 (s, 3H), 2.06 (m, 1H), 1.90 (m, 1H), 1.71 (m, 1H), 1.6–1.15 (m, 9 H), 0.75 (m, 1H). Yield 42%.
- Product **34**: ¹H NMR ((CD₃)₂SO) δ 10.69 (bs, 1H), 9.36 (bs, 1H), 7.15 (d, J = 7.6 Hz, 1H), 7.08 (m, 2H), 7.01 (d, J = 7.6 Hz, 1H), 6.69 (m, 2H), 2.47 (m, 1H), 2.33 (s, 3H), 1.7–1.2 (m, 11 H), 0.85 (m, 1H). HRMS m/z calcd for C₂₂H₂₄ClNO₂ [M+Na], 392.1393; found, 392.1369. Yield 56%.
- (*RS*)-3-(4-Fluorophenyl)-3-(4-hydroxyphenyl)-6-methoxy-7-methylindolin-2-one (35). Preparation of 35 was performed according to general procedure A using 6-methoxy-7-methylindoline-2,3-dione and 4-fluorophenylmagnesium bromide.
- (*RS*)-3-(4-Fluorophenyl)-3-hydroxy-6-methoxy-7-methylindolin-2-one: 1 H NMR ((CD₃)₂SO δ 10.42 (bs, 1H), 7.29 (m, 2H), 7.12 (m, 2H), 6.90 (d, J = 8.2 Hz, 1H,), 6.56 (d, J = 8.2 Hz, 1H), 6.51 (s, 1H), 3.77 (s, 3H), 2.09 (s, 3H). Yield 82%.
- Product **35**: 1 H NMR ((CD₃)₂SO) δ 10.71 (bs, 1H), 9.41 (bs, 1H), 7.15 (m, 4H), 6.95 (m, 3H), 6.69 (m, 2H), 6.59 (d, J = 8.3 Hz, 1H), 3.76 (s, 3H), 2.09 (s, 3H). HRMS m/z calcd for C₂₂H₁₈FNO₃ [M+H], 364.1349; found, 364.1336. Yield 94%.

- (*RS*)-3-Cyclopentyl-3-(4-hydroxyphenyl)-6-methoxy-7-methylindolin-2-one (36). Preparation of 36 was performed according to general procedure A using 6-methoxy-7-methylindoline-2,3-dione and cyclopentylmagnesium bromide.
- (RS)-3-Cyclopentyl-3-hydroxy-6-methoxy-7-methylindolin-2-one: MS $[M+Na]^+= 284.0 [M-H]^+= 260.0$. Yield 27%.
- Product **36**: ¹H NMR ((CD₃)₂SO) δ 10.39 (bs, 1H), 9.27 (bs, 1H), 7.13 (m, 2H), 7.05 (d, J = 8.3 Hz, 1 H), 6.66 (m, 2H), 6.58 (d, J = 8.3 Hz, 1H), 3.78 (s, 3H), 2.92 (m, 1H), 2.06 (s, 3H), 1.6–1.2 (m, 7H), 0.86 (m, 1H). HRMS m/z calcd for C₂₁H₂₃NO₃ [M+Na], 360.1576; found, 360.1593. Yield 56%.
- (*RS*)-3-Cyclohexyl-3-(4-hydroxyphenyl)-6-methoxy-7-methylindolin-2-one (37). Preparation of 37 was performed according to general procedure A using 6-methoxy-7-methylindoline-2,3-dione and cyclohexylmagnesium chloride.
- (*RS*)-3-Cyclohexyl-3-hydroxy-6-methoxy-7-methylindolin-2-one: 1 H-NMR ((CD₃)₂SO) δ 10.19 (bs, 1H), 7.00 (d, J = 8.2 Hz, 1H), 6.51 (d, J = 8.2 Hz, 1H), 5.52 (s, 1H), 3.75 (s, 3H), 2.01 (s, 3H), 1.95–1.4 (m, 6H), 1.25–0.85 (m, 4 H), 0.63 (m, 1H). Yield 51%.
- Product **37**: ¹H NMR ((CD₃)₂SO) δ 10.38 (bs, 1H), 9.28 (bs, 1H), 7.13 (m, 2H), 7.07 (d, , J = 8.2 Hz, 1 H), 6.67 (m, 2H), 6.61 (d, J = 8.2 Hz, 1H), 3.79 (s, 3H), 2.27 (m, 1H), 2.05 (s, 3H), 1.58 (m, 3H), 1.41 (m, 2H), 1.13 (m, 3H), 0.93 (m, 1H), 0.68 (m, 1H). HRMS m/z calcd for $C_{22}H_{25}NO_3$ [M+H], 352.1913; found, 352.1914. Yield 94%.
- (*RS*)-3-Cycloheptyl-3-(4-hydroxyphenyl)-6-methoxy-7-methylindolin-2-one (38). Preparation of 38 was performed according to general procedure A using 6-methoxy-7-methylindoline-2,3-dione and cycloheptylmagnesium bromide.
- (*RS*)-3-Cycloheptyl-3-hydroxy-6-methoxy-7-methylindolin-2-one: 1 H-NMR ((CD₃)₂SO) δ 10.21 (bs, 1H), 7.00 (d, J = 8.3 Hz, 1H), 6.49 (d, J = 8.3 Hz, 1H), 5.58 (s, 1H), 3.75 (s, 3H), 2.08 (m, 1H), 2.01 (s, 3H), 1.88 (m, 1H), 1.73 (m, 1H), 1.55 (m, 1H), 1.50–1.20 (m, 8H), 0.75 (m, 1 H). Yield 35%.
- Product **38**: ¹H NMR ((CD₃)₂SO) δ 10.38 (bs, 1H), 9.28 (bs, 1H), 7.13 (m, 2H), 7.07 (d, , J = 8.2 Hz, 1 H), 6.67 (m, 2H), 6.61 (d, J = 8.2 Hz, 1H), 3.79 (s, 3H), 2.27 (m, 1H), 2.05 (s, 3H), 1.58 (m, 3H), 1.41 (m, 2H), 1.13 (m, 3H), 0.93 (m, 1H), 0.68 (m, 1H). HRMS m/z calcd for C₂₃H₂₇NO₃ [M+Na], 388.1889; found, 388.1936. Yield 90%.
- (S)-3-Cycloheptyl-3-(4-hydroxyphenyl)-6-methoxy-7-methylindolin-2-one (enantiomer 1) [(S)-38]. Preparation of enantiomer 1 of compound 38 was performed according to general procedure B (heptane:EtOH 70:30, 7 mL/min) using racemic compound 38 as starting material. t_R (Chiralcel OD-H column 10×4.0 and 250×4.6 mm ID, 5 micron, heptane:2-PrOH:TFA 80:20:0.1, 0.8 mL/min): 6.4 min.
- (*R*)-3-Cycloheptyl-3-(4-hydroxyphenyl)-6-methoxy-7-methylindolin-2-one (enantiomer 2) [(*R*)-38]. Preparation of enantiomer 2 of compound 38 was performed according to general procedure B (heptane:EtOH 70:30, 7 mL/min) using racemic compound 38 as starting material. t_R (Chiralcel OD-H column 10×4.0 and 250×4.6 mm ID, 5 micron, heptane:2-PrOH:TFA 80:20:0.1, 0.8 mL/min): 7.6 min.

- (2*R*,3'*RS*)-4'-(3'-Cycloheptyl-6'-methoxy-7'-methyl-2'-oxoindolin-3'-yl)phenyl 3,3,3-trifluoro-2-methoxy-2-phenylpropanoate (39). Compund 38 (211 mg, 0.58 mmol) was dissolved in DCM, (*R*)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoic acid (176 mg, 0.75 mmol) was added followed by EDC (166 mg, 0.87 mmol) and DMAP (catalytic amount), left at rt for 7 days, concentrated and the residue was purified by flash chromatography (petroleum ether:EtOAC 10:1) to afford 39 (195 mg, 58%).
- ¹H-NMR (CDCl₃) δ 8.95 (bs, 1H), 7.61 (m, 2H), 7.47 (d, J = 9.0, Hz, 2H), 7.44 (m, 3 H), 7.08 (m, 3H), 6.58 (d, J = 8.2 Hz, 1H), 3.87 (s, 3H), 3.66 (m, 3H), 2.63 (m, 1H), 2.10 (s, 3H), 1.75–1.2 (m, 11H), 0.90 (m, 1H).
- (2*R*,3'*S*)-4'-(3'-Cycloheptyl-6'-methoxy-7'-methyl-2'-oxoindolin-3'-yl)phenyl 3,3,3-trifluoro-2-methoxy-2-phenylpropanoate (diastereomer 1) 39. Preparation of diastereomer 1 of compound 39 was performed using a Chiralcel OD-H guard column ($10 \times 4.0 \text{ mm ID}$, 5 micron) connected to a Chiralcel OD-H column ($250 \times 4.6 \text{ mm ID}$, 5 micron) (heptane:2-PrOH 95:5, 0.7 mL/min) using diastereomeric compound 39 as starting material. t_R : 11.5 min..
- (2*R*,3'*R*)-4'-(3'-Cycloheptyl-6'-methoxy-7'-methyl-2'-oxoindolin-3'-yl)phenyl 3,3,3-trifluoro-2-methoxy-2-phenylpropanoate (diastereomer 2) 39. Preparation of diastereomer 2 of compound 39 was performed using a Chiralcel OD-H guard column ($10 \times 4.0 \text{ mm ID}$, 5 micron) connected to a Chiralcel OD-H column ($250 \times 4.6 \text{ mm}$, ID 5 micron) (heptane:2-PrOH 95:5, 0.7 mL/min) using diastereomeric compound 39 as starting material. t_R : 16.3 min.
- (*S*)-3-Cycloheptyl-3-(4-hydroxyphenyl)-6-methoxy-7-methylindolin-2-one (enantiomer 1) (*S*)-38. An analytical amount of diastereomer 1 of 39 was dissolved in MeOH, 2 M NaOH was added and the reaction mixture was stirred at 40 °C over night. After evaporation *in vacuo* the residue was dissolved in EtOH. t_R (Chiralcel OD-H column 10×4.0 and 250×4.6 mm ID, 5 micron, heptane:2-PrOH:TFA 80:20:0.1, 0.8 mL/min): 6.4 min.
- X-Ray Crystallographic Analysis of (2R,3'S)-4'-(3'-cycloheptyl-6-methoxy-7-methyl-2-oxoindolin-3-yl)phenyl 3,3,3-trifluoro-2-methoxy-2-phenylpropanoate (diastereomer 1) 39. Colorless single crystals were obtained from a solution in hexane. Crystal data: $C_{33}H_{34}F_3NO_5$, Mr 581.6, monoclinic, space group C2 (No. 5), a = 16.4137(8) Å, b = 11.9810(10) Å, c = 15.781(2) Å, $\beta = 104.936(6)^\circ$, V = 2998.5(5) Å³, Z = 4, $D_c = 1.288$ Mg/m³, F(000) = 1224, $\mu(MoK\alpha) = 0.098$ mm⁻¹, crystal size $0.54 \times 0.43 \times 0.46$ mm.

Data Collection and Reduction.

A single crystal was mounted and immersed in a stream of nitrogen gas [T=122(1) K]. Data were collected, using graphite-monochromated Mo $K\alpha$ radiation ($\lambda=0.71073$ Å) on a KappaCCD diffractometer. Data collection and cell refinement were performed using COLLECT¹ and DIRAX² Data reduction was performed using EvalCCD.³ Correction for absorption was performed using Gaussian integration⁴ as included in maXus.⁵

Structure Solution and Refinement.

Positions of all non-hydrogen atoms were found by direct methods^{6,7} Full-matrix least-squares refinements⁸ were performed on F^2 , minimizing $\Sigma w(F_o^2 - kF_c^2)^2$, with anisotropic displacement parameters of the non-hydrogen atoms. The position of hydrogen atoms were located in subsequent difference electron density maps and were included in calculated

position with fixed isotropic displacement parameters ($U_{iso} = 1.2U_{eq}$ for CH, CH₂ and $U_{iso} =$ $1.5U_{eq}$ for CH₃), except for the hydrogen atom bonded to NH. The position of this hydrogen atom was refined with fixed isotropic displacement parameters (U_{iso} = 1.2 U_{eq} for NH). Refinement (385 parameters, 6867 unique reflections) converged at $R_F = 0.026$, $wR_F^2 = 0.069$ [6698 reflections with $F_o > 4\sigma(F_o)$; $w^{-1} = (\sigma^2(F_o^2) + (0.0407P)^2 + 0.9226P)$, where $P = (F_o^2 + 1.0407P)^2 + 0.9226P$ $2F_c^2$)/3; S = 1.062]. The residual electron density varied between -0.15 and 0.30 e Å⁻³. Absolute configuration could not be identified based on the structure determination (Flack parameter = $0.0(3)^9$), but the stereochemistry could be identified relative to the known stereochemistry of the Moshers ester. Complex scattering factors for neutral atoms were taken from International Tables for Crystallography as incorporated in SHELXL97^{8,10}. Crystallographic data for (2R,3'S)-4'-(3'-cycloheptyl-6-methoxy-7-methyl-2-oxoindolin-3yl)phenyl 3,3,3-trifluoro-2-methoxy-2-phenylpropanoate Fractional atomic coordinates, list of anisotropic displacement parameters and a complete list of geometrical data have been deposited in Cambridge Crystallographic Data Centre (No. CCDC 779154). Copies of the data can be obtained, free of charge, on application to the director, CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: +44 1223 336033 or e-mail: deposit@ccdc.cam.ac.uk).




Figure 1. Perspective drawing $(ORTEP-3)^{11}$ of compound (2R,3'S)-4'-(3'-cycloheptyl-6-methoxy-7-methyl-2-oxoindolin-3-yl)phenyl 3,3,3-trifluoro-2-methoxy-2-phenylpropanoate. Displacement ellipsoids of the non-hydrogen atoms are shown at the 50% probability level. Hydrogen atoms have been left out for clarity.

References

- 1. COLLECT, data collection software; Nonius BV: Delft, The Netherlands, 1999.
- 2. Duisenberg, A. J. M. Indexing in single-crystal diffractometry with an obstinate list of reflections. *J. Appl. Crystallogr.* **1992**, *25*, 92-96.
- 3. Duisenberg, A. J. M. Reflections on area detectors: ab initio calculation of single-crystal x-ray reflection contours. Ph.D. Thesis, University of Utrecht, The Netherlands, 1998
- 4. Coppens, P. Evaluation of absorption and extinction in single-crystal structure analysis. In Crystallographic Computing; Ahmed, F. R., Hall, S. R., Huber, C. P. Eds.; Munksgaard: Copenhagen, **1970**, 255-270.
- 5. Mackay, S.; Gilmore, C. J.; Edwards, C.; Stewart, N.; Shankland, K. *maXus* Computer Program for the Solution and Refinement of Crystal Structures; Bruker Nonius: The Netherlands, Mac-Science: Japan, & The University of Glasgow, **1999**.
- 6. Sheldrick, G. M. Phase annealing in SHELX-90: direct methods for larger structures. *Acta Crystallogr.* **1990**, A46, 467-473.
- 7. Sheldrick, G. M. SHELXS97; Program for the Solution of Crystal Structures; University of Göttingen: Göttingen, Germany, **1997**.
- 8. Sheldrick, G. M. SHELXL97, Program for Crystal Structure Refinement; University of Göttingen: Göttingen, Germany, **1997**.
- 9. Flack H. D. On enantiomorph-polarity estimation. *Acta Crystallogr.* **1983**, *A39*, 876-881.
- 10. International Tables for Crystallography; Wilson, A. J. C., Ed.; Kluwer Academic Publishers: Dordrecht, The Netherlands, **1995**; Vol. C, Tables 4.2.6.8 and 6.1.1.4.
- 11. Farrugia, L. J. ORTEP-3 for Windows a version of ORTEP-III with a Graphical User Interface (GUI). *J. Appl. Crystallogr.* **1997**, *30*, 565.